<DOC>
	<DOCNO>NCT00547729</DOCNO>
	<brief_summary>Most people heart failure take number medication work different way . Patients family need keep track prescribed medication follow instruction much take take . Currently , doctor guide primarily symptom . The device study trial ( call HeartPODâ„¢ System ) monitor heart function inside body alert patient physician necessary change medication .</brief_summary>
	<brief_title>Hemodynamically Guided Home Self-Therapy Severe Heart Failure Patients ( HOMEOSTASIS )</brief_title>
	<detailed_description>The Sponsor believe direct measurement heart may provide accurate , reliable medically acceptable way tell doctor CHF worsening hour day symptom would develop would notice . This may enable doctor take preventative measure avoid hospitalization .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Age &gt; 18 &lt; 85 . Documented history congestive heart failure result ischemic nonischemic cardiomyopathy systolic diastolic dysfunction least 6 month duration . Patients LVEF &lt; 40 % receive maximally tolerate dos ACEI ( ARB ACEI tolerate ) , beta blocker , antialdosterone therapy . The combination hydralazine nitrate consider persistently symptomatic African American patient . A history NYHA Class II ( OUS ) , III IV symptom . Minimum one ( 1 ) prior hospital admission within last 12 month exacerbation CHF one ( 1 ) presentation Emergency Department Clinic require parenteral diuretic , vasodilator , inotrope , nesiritide , equivalent treatment . Female subject childbearing potential must negative pregnancy test within seven ( 7 ) day procedure . Central venous vascular access . Capable Valsalva maneuver airway pressure &gt; 40 mm Hg 10 second . The subject treating physician agree subject comply require postprocedure followup , patient capable correct device use outline protocol . Written informed consent . Intractable HF resting symptom despite maximal medical therapy active listing cardiac transplantation ( &lt; 6 month survival expect ) . Resting systolic blood pressure &lt; 90 &gt; 180 mmHg . Acute MI , unstable ischemic syndrome within last 6 week . Percutaneous coronary intervention ( PCI ) cardiac surgery perform plan within 6 week . Coexisting stenotic valve lesion , vegetation , hypertrophic cardiomyopathy , amyloidosis infiltrative heart disease , constrictive , restrictive disease , tamponade , moderate large pericardial effusion . Subject history deep venous thrombosis pulmonary embolism . Surgical correction congenital heart disease involve atrial septum . CVA TIA within 6 month . History uncorrected cerebral vascular disease . Atrial ventricular thrombus , tumor systemic thromboembolism . Chronic atrial fibrillation . Symptomatic bradyarrhythmia sustain VT/VF unless successfully treat cardiac rhythm management device 6 week . Atrial septal defect patent foramen ovale &gt; 2 mm diameter . Life expectancy &lt; 1 year malignancy , primary pulmonary hypertension , renal , hepatic , neurological condition , etc . Gastrointestinal bleeding last 6 month . Coagulopathy uninterruptible anticoagulation therapy unable take antiplatelet medication . Creatinine &gt; 2.5 gm/dl Temperature &gt; 37.8C white blood cell count ( WBC ) &gt; 13,000/mm3 . The subject currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Left Atrial Pressure Monitoring</keyword>
</DOC>